TERN Earnings
Thursday, May 07 2026
EPS Estimate
$-0.25
$-0.29 – $-0.19
Current Price
$52.86
Our Position
bullishLeerink initiates TERN at Outperform, $4.8B leukemia drug upside
structured data
est. revisions rising
(+8.9pp / 30d)
A major biotech analyst putting a 6-figure price target on an unproven drug is a big signal, but execution risk is real. TERN-701 hasn't cleared late-stage trials yet, so the $4.8B thesis hinges entirely on Phase 3 success and regulatory approval. This is a binary bet on a single asset masquerading as an analyst call.
Watch: Watch for TERN-701 Phase 3 data and FDA interactions — that's the catalyst that either validates or blows up Leerink's $58 target. Hedge fund accumulation matters only if the drug works.
Data Signal Summary
2 bullish
2 bearish
Estimates up +12%
Insider buying cluster
Put/call 10.1 (bearish skew)
Price downtrend
Key Context
Analyst Consensus
mixed
Insider Activity
selling
Price Trend
downtrend
From 52w High
0.0%
Est. Revisions (30d)
+12.5% 2up/1dn
Analyst Target (mean)
$54 $53–$58 +1%
Options P/C Ratio
10.10
Est. Dispersion
40% 6 analysts
Insider Cluster
strong buy (officer)
Fund Convergence
strong Citadel, D.E. Shaw, Renaissance
Recent Activity
insider trades
35 transactions
Sell
·
KURIAKOSE EMIL T. (Officer)
·1,155 shares
·$44,552
Sell
·
QUIGLEY JILL M. (Director)
·24,520 shares
·$441,360
Sell
·
KURIAKOSE EMIL T. (Officer)
·942 shares
·$49,693
Sell
·
BURROUGHS AMY LOUISE (Chief Executive Officer)
·14,583 shares
·$681,108
Exercise
·
BURROUGHS AMY LOUISE (Chief Executive Officer)
·14,583 shares
·$67,665
30 more
Sell
·
BURROUGHS AMY LOUISE
·14,583 shr
·$571,579
Sell
·
BURROUGHS AMY LOUISE
·68,749 shr
·$2,548,603
Exercise
·
BURROUGHS AMY LOUISE
·68,749 shr
·$318,995
Award
·
GENGOS ANDREW
·68,750 shr
Award
·
BURROUGHS AMY LOUISE
·150,000 shr
Award
·
KURIAKOSE EMIL T.
·56,250 shr
Sell
·
BURROUGHS AMY LOUISE
·71,339 shr
·$2,718,230
Exercise
·
BURROUGHS AMY LOUISE
·171,551 shr
·$99,997
Exercise
·
QUIGLEY JILL M.
·24,520 shr
·$226,565
Sell
·
KURIAKOSE EMIL T.
·944 shr
·$7,407
Sell
·
KURIAKOSE EMIL T.
·853 shr
·$3,640
Buy
·
GENGOS ANDREW
·10,000 shr
·$39,283
Buy
·
BURROUGHS AMY LOUISE
·23,314 shr
·$90,230
Buy
·
GENGOS ANDREW
·15,000 shr
·$57,082
Sell
·
KURIAKOSE EMIL T.
·952 shr
·$2,366
Sell
·
VIGNOLA MARK J.
·17,188 shr
·$99,024
Sell
·
QUIGLEY JILL M.
·15,000 shr
·$86,460
Sell
·
KURIAKOSE EMIL T.
·4,481 shr
·$25,607
Buy
·
BURROUGHS AMY LOUISE
·510 shr
·$2,606
Buy
·
LU HONGBO B
·476,190 shr
·$4,999,995
Sell
·
VIGNOLA MARK J.
·10,000 shr
·$110,000
Exercise
·
VIGNOLA MARK J.
·10,000 shr
·$53,600
Sell
·
QUIGLEY JILL M.
·17,235 shr
·$172,350
Exercise
·
QUIGLEY JILL M.
·17,235 shr
·$31,368
Sell
·
QUIGLEY JILL M.
·15,000 shr
·$113,580
Sell
·
GORDON CARL L
·56,164 shr
·$561,640
Sell
·
ORBIMED ADVISORS, L.L.C.
·56,164 shr
·$561,640
Sell
·
QUIGLEY JILL M.
·14,765 shr
·$147,660
Exercise
·
QUIGLEY JILL M.
·14,765 shr
·$26,872
Buy
·
YOON SEOKHO BRYAN
·4,791 shr
·$28,794
analyst ratings
1 rating
JP Morgan
→Overweight
8d ago
ae trade
2
3d ago
6d ago
Explore more
